Stone disease: Diagnosis and medical management

European Urology

Volumn 41, Issue 5, 2002, Pages 1-11

  Tiselius, H G ^a   Ackermann, D ^b   Hess, B ^c   Boeve E ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^c Hospital Zimmerberg   (Switzerland)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHYDROXAMIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; BICARBONATE; BUCILLAMINE; CALCIUM OXALATE; CALCIUM PHOSPHATE; CAPTOPRIL; CELLULOSE PHOSPHATE; CHELATING AGENT; CITRATE POTASSIUM; CITRATE SODIUM; CITRIC ACID; CYSTINE; HYDROXYUREA; MAGNESIUM; OXALIC ACID; PARATHYROID HORMONE; PENICILLAMINE; PENICILLIN DERIVATIVE; PLACEBO; POTASSIUM DIHYDROGEN PHOSPHATE; PURINE; TETRACYCLINE; THIAZIDE DIURETIC AGENT; TIOPRONIN; UNINDEXED DRUG; UREASE INHIBITOR; URIC ACID; URICOSURIC AGENT;

AMINOACIDURIA; CALCIUM BLOOD LEVEL; CHELATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTINURIA; DIAGNOSTIC TEST; DIETARY INTAKE; DRUG COST; DRUG INDICATION; EXTRACORPOREAL LITHOTRIPSY; HUMAN; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STONE FORMATION; URIC ACID STONE; UROLITHIASIS;

EID: 0036587066     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00045-3     Document Type: Article

References (24)

1. Ahlstrand C, Tiselius H-G. Recurrences during a 10 years follow-up after first renal stone episode. Urol Res 1990;18:397-9.
2. Boulahrouz R, et al. In: Jungers P, Daudon M, editors. Renal stone disease. Amsterdam: Elsevier, 1997, p. 6-7.
3. Williams RE. Long-term survey of 538 patients with upper urinary tract stone. Br J Urol 1963;35:416-37.
4. Hofbauer J, Hobarth K, Ludvik G, Marberger M. The stone clinic effect: myth or reality? Eur Urol 1994;26:309-13.
5. Wasserstein AAG, Stolley PD, Soper KA, Goldfarb S, Maislin G, Agus Z. Case-control study of risk factors for idiopathic calcium nephrolithiasis. Miner Electrolyte Metab 1987;13(2):85-95.
6. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5 years randomised prospective study. J Urol 1996;155:839-43.
7. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. New Engl J Med 1993;328:833-8.
8. Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Int Med 1997;126:497-504.
9. Robertson WG, Peacock M. The cause of idiopathic calcium stone disease: Hypercalciuria or hyperoxaluria? Nephron 1980;26:105-10.
10. Fuss M, Pepersack T, Van Geel J, et al. Involvement of low-calcium diet in the reduced bone mineral content of idiopathic renal stone formers. Calcif Tissue Int 1990;46:9-13.
11. Hess B, Casez J-P, Takkinen R, Ackermann D, Jaeger Ph. Relative hypoparathyroidism and calcitriol up-regulation in hypercalciuric calcium renal stone formers: impact of nutrition. Am J Nephrol 1993;13:18-26.
12. Hess B, Jost C, Zipperle L, et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallisation during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998;13:2241-7.
13. Goldfarb S. Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiasis. Kidney Int 1988;34:544-55.
14. Hiatt RA, Ettinger B, Caen B, et al. Randomised controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25-33.
15. Iguchi M, Umekawa T, Ishikawa Y, et al. Clinical effects of prophylactic dietary treatment on renal stones. J Urol 1990;144:229-32.
16. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium does not. J Urol 1988;139:679-84.
17. Yendt ER, Cohanim M. Prevention of calcium stones with thiazides. Kidney Int 1978;13:397-409.
18. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis: A double-blind study in clinical practice. Acta Med Scand 1984;215:383-9.
19. Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol 1986;18: 265-9.
20. Barcelo P, Wuhl O, Servitge E, et al. Randomised double-blind study of potassium citrate in idiopathic hypocitraturia calcium nephrolithiasis. J Urol 1993; 150:1761-4.
21. Hofbauer J, Höbarth K, Szabo N, Marberger M. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis: A prospective randomised study. Br J Urol 1994;73:362-5.
22. Ettinger B, Tang A, Citron JT, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069-73.
23. Ettinger B, Tang A, Citron JT, et al. Randomised clinical trial of allopurinol in the prevention of calcium oxalate calculi. New Engl J Med 1986; 315:1386-9.
24. Parks JH, Coe FLC. The financial effects of kidney stone prevention. Kidney Int 1996;50:1706-12.